Regeneron 2026: Revenue $5.12B, EPS $18.45— 10-Q Summary
Regeneron Pharmaceuticals reported 2026 revenue of $5.12B, up 36.3% YoY, and net income of $1.95B, up 33.5%. EPS rose 35.5% to $18.45. Growth driven by Dupixent, EYLEA HD, and Libtayo sales. FDA approved two new drugs. Capital spending expected at $1.05B-$1.10B.
How this was made
The 30-second read
Why it matters
Traders can update earnings models using the reported revenue, net income, and diluted EPS, and adjust expectations for franchise performance (Dupixent, EYLEA HD, Libtayo) versus competitive pressure (EYLEA decline).
Market read
Fresh 10-Q datapoints (revenue, net income, diluted EPS) and detailed franchise sales trends provide actionable inputs for near-term biotech positioning.
What to watch
The summary mentions FDA approvals and Limerick facility repairs returning to normal, but it does not quantify guidance beyond capex, leaving uncertainty around forward revenue trajectory and margin drivers.
Background
The piece is an AI summary of Regeneron’s SEC 10-Q filed Oct. 30, 2026, highlighting financial results and key business/product updates.
Ticker impact
Regeneron reported 2026-period revenue of $5.12B and diluted EPS of $18.45, plus Dupixent, EYLEA HD, and Libtayo sales updates in its 10-Q summary.
Likely upward bias as investors focus on accelerating EPS and strong growth in key franchises, partially offset by EYLEA sales decline.
The article provides concrete financial datapoints (revenue, net income, diluted EPS) and specific product sales trends, which typically drive near-term repricing around earnings expectations.
Market effects
Biopharma investors may recalibrate read-through on ophthalmology and immunology franchise durability based on EYLEA HD share gains versus EYLEA declines.
Limited direct regional spillover; primarily US-listed biotech sentiment.
Moderate, as FDA approvals and global sales trends can influence broader biotech risk appetite.
Counterpoint
Strong Dupixent and EYLEA HD growth may be partly offset by competitive erosion in EYLEA, so the net quality of growth could be less durable than headline EPS suggests.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
US-listed biotech issuer reporting 2026-period revenue, net income, and diluted EPS, plus product and FDA approval updates in its 10-Q summary.
- productDupixent
Dupixent collaboration sales grew 35% in the quarter per the summary.
- productEYLEA HD
EYLEA HD sales increased 63% in the quarter per the summary.
- productLibtayo
Libtayo sales rose 51% in the quarter per the summary.
- productEYLEA
EYLEA sales declined 49% amid competition and patient switching to EYLEA HD per the summary.
